GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Durata Therapeutics Inc (FRA:DTA) » Definitions » PB Ratio

Durata Therapeutics (FRA:DTA) PB Ratio : (As of May. 18, 2024)


View and export this data going back to . Start your Free Trial

What is Durata Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-18), Durata Therapeutics's share price is €18.88. Durata Therapeutics's Book Value per Share for the quarter that ended in Sep. 2014 was €-0.47. Hence, Durata Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Durata Therapeutics's PB Ratio or its related term are showing as below:

During the past 3 years, Durata Therapeutics's highest PB Ratio was 241.00. The lowest was 0.00. And the median was 0.00.

FRA:DTA's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.55
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Durata Therapeutics's average Book Value Per Share Growth Rate was -129.90% per year.

Back to Basics: PB Ratio


Durata Therapeutics PB Ratio Historical Data

The historical data trend for Durata Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durata Therapeutics PB Ratio Chart

Durata Therapeutics Annual Data
Trend Dec11 Dec12 Dec13
PB Ratio
- - 7.95

Durata Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.61 7.95 18.53 - -

Competitive Comparison of Durata Therapeutics's PB Ratio

For the Biotechnology subindustry, Durata Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Durata Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Durata Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Durata Therapeutics's PB Ratio falls into.



Durata Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Durata Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2014)
=18.88/-0.466
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Durata Therapeutics  (FRA:DTA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Durata Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Durata Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Durata Therapeutics (FRA:DTA) Business Description

Traded in Other Exchanges
N/A
Address
Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.

Durata Therapeutics (FRA:DTA) Headlines

No Headlines